|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||50.77 - 52.19|
|52 Week Range||29.15 - 55.91|
|PE Ratio (TTM)||30.48|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Emergent's (EBS) earnings and revenues lag estimates in Q1. However, the top line improves marginally year over year, driven by higher contract manufacturing revenues.
On a per-share basis, the Gaithersburg, Maryland-based company said it had a loss of 10 cents. Losses, adjusted for non-recurring costs, were 3 cents per share. The results fell short of Wall Street expectations. ...
Specialty biopharma Emergent Biosolutions Inc (NYSE: EBS ) has seen its stock rise more than 40 percent over the past two years, and investors shouldn't expect to see such outsized returns going forward, ...
This could indicate that investors who seek to profit from falling equity prices are not currently targeting EBS. Over the last one-month, outflows of investor capital in ETFs holding EBS totaled $497 million.
The Gaithersburg-based biotech just received approval to introduce its anthrax vaccine in five European countries, a move that brings the possibility of a new and important revenue stream.
In October 2017, Emergent BioSolutions (EBS) completed the acquisition of raxibacumab from GlaxoSmithKline (GSK). Raxibacumab is a fully human monoclonal antibody with approval from the FDA for treating inhalational anthrax. Raxibacumab has orphan drug designation in the US and was approved by the FDA in 2012.
Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
For $50 and the cost of shipping on Amazon , you could get the same protection against chemical weapons that Gaithersburg's Emergent BioSolutions sells to protect soldiers on the ground. If you hit purchase, you would get what's called a reactive skin decontamination lotion kit. Inside are a sponge and specialized lotion cleared by the U.S. Food and Drug Administration to remove or neutralize such chemical warfare agents as sarin and mustard gas from the skin in a single step.
Emergent's (EBS) earnings and revenues beat estimates in Q4. The top line also improves year over year on higher product sales.
The Gaithersburg, Maryland-based company said it had net income of 67 cents per share. Earnings, adjusted for non-recurring costs, were 74 cents per share. The results surpassed Wall Street expectations. ...
Emergent BioSolutions Inc’s (NYSE:EBS) most recent return on equity was a substandard 12.20% relative to its industry performance of 16.59% over the past year. EBS’s results could indicate a relativelyRead More...
Nationally, among the biggest losers as of Monday was Seattle-based radio technology and software maker Impinj Inc. (PI), which saw its stock price plummet 45 percent to $11.94 between Jan. 29 and Feb. 5. The slide follows a stretch that saw U.S. stocks hit historic highs amid investor excitement over strong corporate earnings reports, a growing economy and the passage of a business-friendly tax bill. Last month, the stalwart Dow Jones Industrial Average took just seven days to add 1,000 points and surpass 26,000 for the first time in its history. Gina Martin Adams, chief equity strategist for Bloomberg Intelligence, said investors were overly optimistic in 2017 amid a steady stream of strong corporate earnings reports.
Several D.C.-area publicly traded companies saw their stock prices hit in recent days as U.S. stock exchanges saw a widespread selloff Friday, continuing into Monday trading. In the worst stock market ...
We see a notable shift away from traditional large-cap pharmaceutical stocks to more specialized niches.
Emergent (EBS) provides preliminary results for 2017 and its guidance for 2018. The results exceed management's outlook issued in November last year.